Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Patrice S. Obermiller"'
Publikováno v:
Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743140900bc72eb87b804c1cdfc2b0c5
https://doi.org/10.1201/9781003064657-12
https://doi.org/10.1201/9781003064657-12
Publikováno v:
Breast Cancer Research
Gene therapy is a therapeutic approach that is designed to correct specific molecular defects that contribute to the cause or progression of cancer. Genes that are mutated or deleted in cancers include the cancer susceptibility genes p53 and BRCA1. B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233f77ea377038321b79acd208f79bcc
http://europepmc.org/articles/PMC521211
http://europepmc.org/articles/PMC521211
Autor:
Jennifer Meyers, John R. Apgar, Walter Eckhart, Nathan A. Berger, Patrice S. Obermiller, David S. Ucker
Publikováno v:
Molecular and Cellular Biology. 12:3060-3069
We examined virally transformed murine fibroblast clones as targets for cytotoxic T lymphocyte (CTL)-triggered lysis and genome digestion. Strikingly, while all clones were essentially equivalent in the ability to be lysed, one clone, SV3T3-B2.1, fai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6e129faaad6cbd0e3cb86f734be9aa
https://doi.org/10.1128/mcb.12.7.3060
https://doi.org/10.1128/mcb.12.7.3060
Autor:
Patrice S. Obermiller, Jeffrey T. Holt
The human breast and ovarian cancer susceptibility gene BRCA1 is a tumorsuppressor gene which is mutated and lost in hereditary breast and ovarian cancer, and has both alleles mutated in approximately 10-15% of cases of sporadic ovarian cancer. Studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b077f7d91b5ba106e623f8eea67a605
https://doi.org/10.1385/1-59259-086-1:593
https://doi.org/10.1385/1-59259-086-1:593
Publikováno v:
Gynecologic oncology. 79(3)
Objective. The aim of this study was to determine the preclinical stability, toxicity, and efficacy of a second-generation complement-resistant retroviral BRCA1 vector, MFG-BRCA1, for ovarian cancer gene therapy. Methods. MFG-BRCA1 was packaged in hu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27fd5b3b372527f6b1bd24d421fadc42
https://pubmed.ncbi.nlm.nih.gov/11104622
https://pubmed.ncbi.nlm.nih.gov/11104622
Publikováno v:
Hematology/oncology clinics of North America. 12(3)
Retroviral-mediated delivery of BRCA1 gene therapy (LXN-BRCA1sv, a normal splice variant form of BRCA1) was tested extensively in mouse models. It was found to be effective in reducing tumor burden and to be minimally toxic. Twelve phase I clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79f69ed6b94766da38be5fca9c45045
https://pubmed.ncbi.nlm.nih.gov/9684097
https://pubmed.ncbi.nlm.nih.gov/9684097
Publikováno v:
Nature genetics. 9(4)
We have characterized expression of the familial breast and ovarian cancer gene, BRCA1, in cases of non-hereditary (sporadic) breast cancer and analyzed the effect of antisense inhibition of BRCA1 on the proliferative rate of mammary epithelial cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1636a53d4446f659ded17e1d569e8b7
https://pubmed.ncbi.nlm.nih.gov/7795653
https://pubmed.ncbi.nlm.nih.gov/7795653